HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2018 Dec 18

PMID 30555417

Citations 14

Authors

Emily E Morin

Xiang-An Li

Anna Schwendeman

Affiliations

Soon will be listed here.

Abstract

High-density lipoprotein (HDL) have long been studied for their protective role against cardiovascular diseases, however recently relationship between HDL and cancer came into focus. Several epidemiological studies have shown an inverse correlation between HDL-cholesterol (HDL-C) and cancer risk, and some have even implied that HDL-C can be used as a predictive measure for survival prognosis in for specific sub-population of certain types of cancer. HDL itself is an endogenous nanoparticle capable of removing excess cholesterol from the periphery and returning it to the liver for excretion. One of the main receptors for HDL, scavenger receptor type B-I (SR-BI), is highly upregulated in endocrine cancers, notably due to the high demand for cholesterol by cancer cells. Thus, the potential to exploit administration of cholesterol-free reconstituted or synthetic HDL (sHDL) to deplete cholesterol in endocrine cancer cell and stunt their growth of use chemotherapeutic drug loaded sHDL to target payload delivery to cancer cell has become increasingly attractive. This review focuses on the role of HDL and HDL-C in cancer and application of sHDLs as endocrine cancer therapeutics.

Citing Articles

Metabolic dysfunction-associated profiles and subsequent site-specific risk of obesity-related cancers among Chinese patients with diabetes: a retrospective cohort study.

Yau S, Leung E, Wong M, Hung C, Chong K, Lee A BMJ Open. 2024; 14(4):e082414.

PMID: 38569684 PMC: 11146369. DOI: 10.1136/bmjopen-2023-082414.

Cumulative exposure to metabolic syndrome increases thyroid cancer risk in young adults: a population-based cohort study.

Kim J, Han K, Kim M, Baek K, Song K, Kwon H Korean J Intern Med. 2023; 38(4):526-533.

PMID: 37198877 PMC: 10338240. DOI: 10.3904/kjim.2022.405.

[HDL - Quo vadis].

von Eckardstein A, Marz W, Laufs U Dtsch Med Wochenschr. 2023; 148(10):627-635.

PMID: 37080216 PMC: 10139774. DOI: 10.1055/a-1516-2731.

The characteristics of serum lipid spectrum in PanNENs and its correlation with clinicopathological features and prognosis.

Meng Y, Fan Z, Yang J, Li Y, Liu S, Gao C Front Endocrinol (Lausanne). 2023; 14:1137911.

PMID: 37033225 PMC: 10081680. DOI: 10.3389/fendo.2023.1137911.

The associations between serum high-density lipoprotein cholesterol levels and malignant behavior in pancreatic neuroendocrine neoplasms.

Quan L, Liu Y, Cui W, Wang X, Zhang W, Wang Z Lipids Health Dis. 2022; 21(1):58.

PMID: 35842659 PMC: 9287928. DOI: 10.1186/s12944-022-01669-z.

References

Hu J, Zhang Z, Shen W, Azhar S . Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab (Lond). 2010; 7:47. PMC: 2890697. DOI: 10.1186/1743-7075-7-47. View

Gutierrez-Pajares J, Hassen C, Chevalier S, Frank P . SR-BI: Linking Cholesterol and Lipoprotein Metabolism with Breast and Prostate Cancer. Front Pharmacol. 2016; 7:338. PMC: 5054001. DOI: 10.3389/fphar.2016.00338. View

Martin L, Melnichouk O, Huszti E, Connelly P, Greenberg C, Minkin S . Serum lipids, lipoproteins, and risk of breast cancer: a nested case-control study using multiple time points. J Natl Cancer Inst. 2015; 107(5). PMC: 4822522. DOI: 10.1093/jnci/djv032. View

Taylor M, Sanjanwala A, Morin E, Rowland-Fisher E, Anderson K, Schwendeman A . Synthetic High-Density Lipoprotein (sHDL) Inhibits Steroid Production in HAC15 Adrenal Cells. Endocrinology. 2016; 157(8):3122-9. PMC: 4967112. DOI: 10.1210/en.2014-1663. View

Zhang Z, Bast Jr R, Yu Y, Li J, Sokoll L, Rai A . Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004; 64(16):5882-90. DOI: 10.1158/0008-5472.CAN-04-0746. View

Guo S, He X, Chen Q, Yang G, Yao K, Dong P . The Effect of Preoperative Apolipoprotein A-I on the Prognosis of Surgical Renal Cell Carcinoma: A Retrospective Large Sample Study. Medicine (Baltimore). 2016; 95(12):e3147. PMC: 4998392. DOI: 10.1097/MD.0000000000003147. View

Klimstra D, Modlin I, Coppola D, Lloyd R, Suster S . The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39(6):707-12. DOI: 10.1097/MPA.0b013e3181ec124e. View

Alwaili K, Bailey D, Awan Z, Bailey S, Ruel I, Hafiane A . The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta. 2011; 1821(3):405-15. DOI: 10.1016/j.bbalip.2011.07.013. View

Resnik N, Repnik U, Kreft M, Sepcic K, Macek P, Turk B . Highly Selective Anti-Cancer Activity of Cholesterol-Interacting Agents Methyl-β-Cyclodextrin and Ostreolysin A/Pleurotolysin B Protein Complex on Urothelial Cancer Cells. PLoS One. 2015; 10(9):e0137878. PMC: 4567298. DOI: 10.1371/journal.pone.0137878. View

10.

Connelly M, Williams D . SR-BI and cholesterol uptake into steroidogenic cells. Trends Endocrinol Metab. 2003; 14(10):467-72. DOI: 10.1016/j.tem.2003.10.002. View

11.

Vaisar T, Tang C, Babenko I, Hutchins P, Wimberger J, Suffredini A . Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. J Lipid Res. 2015; 56(8):1519-30. PMC: 4513993. DOI: 10.1194/jlr.M059089. View

12.

Su F, Grijalva V, Navab K, Ganapathy E, Meriwether D, Imaizumi S . HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther. 2012; 11(6):1311-9. PMC: 3374063. DOI: 10.1158/1535-7163.MCT-11-0905. View

13.

Krause B, Remaley A . Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr Opin Lipidol. 2013; 24(6):480-6. DOI: 10.1097/MOL.0000000000000020. View

14.

Kuai R, Li D, Chen Y, Moon J, Schwendeman A . High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano. 2016; 10(3):3015-41. PMC: 4918468. DOI: 10.1021/acsnano.5b07522. View

15.

Furberg A, Veierod M, Wilsgaard T, Bernstein L, Thune I . Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst. 2004; 96(15):1152-60. DOI: 10.1093/jnci/djh216. View

16.

Pan B, Ren H, He Y, Lv X, Ma Y, Li J . HDL of patients with type 2 diabetes mellitus elevates the capability of promoting breast cancer metastasis. Clin Cancer Res. 2012; 18(5):1246-56. DOI: 10.1158/1078-0432.CCR-11-0817. View

17.

Cust A, Kaaks R, Friedenreich C, Bonnet F, Laville M, Tjonneland A . Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2007; 14(3):755-67. DOI: 10.1677/ERC-07-0132. View

18.

Namiri-Kalantari R, Gao F, Chattopadhyay A, Wheeler A, Navab K, Farias-Eisner R . The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory. Biofactors. 2015; 41(3):153-9. DOI: 10.1002/biof.1205. View

19.

Jafri H, Alsheikh-Ali A, Karas R . Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol. 2010; 55(25):2846-54. DOI: 10.1016/j.jacc.2009.12.069. View

20.

Li X, Tang H, Wang J, Xie X, Liu P, Kong Y . The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast. 2016; 32:1-6. DOI: 10.1016/j.breast.2016.11.024. View